Search
Abiraterone
go.drugbank.com/drugs/DB05812ApprovedInvestigationalAbiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis … [L40968, L40193, L47740, L47745] and when used in combination with niraparib, BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor. … [A187547,A187556] It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer.[L34288] This mutation makes up >50% of all KRAS mutations.
Finafloxacin
go.drugbank.com/drugs/DB09047ApprovedWithdrawnFinafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.
Categories: Topoisomerase II InhibitorsEucalyptus oil
go.drugbank.com/drugs/DB11114ApprovedIt is shown to be effective in reducing pain, swelling, and inflammation via its modulatory effect on the immune response. … It is also shown to exhibit antibacterial activity against some bacterial species and cough suppressant actions.
Mixtures: Cellzyme ON-TOX, Cellzyme ON-TOXSacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. … [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601]
Folitixorin calcium
go.drugbank.com/drugs/DB05308InvestigationalCoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer. … ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU).
Daprodustat
go.drugbank.com/drugs/DB11682ApprovedInvestigational[A254172] In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia. … [A254157] A phase 3 clinical trial (NCT02879305) found that in patients with CKD undergoing dialysis, daprodustat was non-inferior to erythropoiesis-stimulating agents regarding the change in the hemoglobin
Synonyms: Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-Polyethylene glycol 400
go.drugbank.com/drugs/DB11077ApprovedInvestigationalIt is used in ophthalmic solutions for the relief of burning, irritation and/or discomfort that follows dryness of the eye [L1785]. … It is very hydrophilic, which renders it a useful ingredient in drug formulations to augment the solubility and bioavailability of weakly water-soluble drugs.
Mixtures: i-Drops LUBRICANT EYE DROPS, i-Drops LUBRICANT EYE DROPSCategories: Compounds used in a research, industrial, or household settingCalfactant
go.drugbank.com/drugs/DB06415ApprovedInvestigationalIt is an off-white suspension of an extract of natural surfactant from calf lungs suspended in 0.9% saline. … Calfactant is approved for use in the United States of America. It is used to prevent or treat respiratory distress syndrome in premature infants with lung surfactant deficiency.